Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

Bookmark and Share
Published: 31 May 2014
Views: 2552
Dr John Byrd - The Ohio State University, Columbus, USA

At a press conference at ASCO 2014, Dr Byrd presents the early findings from the phase III RESONATE study which indicate that ibrutinib yields lasting tumour responses and marked improvement in survival over standard of atumumab for patients with relapsed chronic lymphocytic leukaemia (CLL).

Read the article for more.